SCYNEXIS Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and In Vitro Activity Against Candida Species at the 31st ECCMID
July 12, 2021 08:00 ET
|
Scynexis
FURI and CARES presentations show ibrexafungerp’s strong clinical response in difficult-to-treat and refractory fungal infections in the hospital setting including Candida aurisIn vitro data...
SCYNEXIS to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference
July 07, 2021 08:30 ET
|
Scynexis
JERSEY CITY, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2021 16:01 ET
|
Scynexis
JERSEY CITY, N.J., July 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)
June 23, 2021 08:30 ET
|
Scynexis
BREXAFEMME, a one-day, novel, oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp antifungal development pipeline and the first approved drug from a...
SCYNEXIS to Present at the BIO Digital International Convention 2021
June 11, 2021 08:30 ET
|
Scynexis
Company presentation will highlight BREXAFEMME® (ibrexafungerp tablets), the first FDA-approved product in the ibrexafungerp development pipeline, in addition to ongoing programs in the hospital...
SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections
June 09, 2021 08:30 ET
|
Scynexis
BREXAFEMME to receive 5-year exclusivity extension under the GAIN Act for a total of 10 years of regulatory exclusivityBREXAFEMME also protected by composition-of-matter patent until 2035Commercial...
SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections
June 02, 2021 07:30 ET
|
Scynexis
Approval of BREXAFEMME (ibrexafungerp) represents the first approved drug in a novel antifungal class in more than 20 yearsBREXAFEMME, a one-day oral treatment for vaginal yeast infection, is the...
SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 17, 2021 08:30 ET
|
Scynexis
Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon...
SCYNEXIS Secures Term Loan Facility for up to $60 Million with Hercules Capital and Silicon Valley Bank
May 14, 2021 08:30 ET
|
Scynexis
Together with SCYNEXIS’ $93M cash balance at 12/31/20, the non-dilutive capital injections from this term loan, the recent licensing payments from Hansoh Pharma, and the monetization of 2020 New...
SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch
May 11, 2021 08:30 ET
|
Scynexis
Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and...